Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $4.3 million.

  • Coherus Oncology's Change in Receivables rose 15464.33% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.2 million, marking a year-over-year decrease of 22311.76%. This contributed to the annual value of -$149.4 million for FY2024, which is 19911.54% down from last year.
  • Coherus Oncology's Change in Receivables amounted to $4.3 million in Q3 2025, which was up 15464.33% from -$55.3 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Change in Receivables high stood at $75.3 million for Q3 2023, and its period low was -$76.6 million during Q2 2024.
  • Over the past 5 years, Coherus Oncology's median Change in Receivables value was -$7.8 million (recorded in 2024), while the average stood at -$7.8 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 308495.51% in 2023, then tumbled by 49320.43% in 2025.
  • Over the past 5 years, Coherus Oncology's Change in Receivables (Quarter) stood at -$13.3 million in 2021, then surged by 240.91% to $18.8 million in 2022, then soared by 134.38% to $44.1 million in 2023, then crashed by 227.85% to -$56.3 million in 2024, then surged by 107.57% to $4.3 million in 2025.
  • Its last three reported values are $4.3 million in Q3 2025, -$55.3 million for Q2 2025, and -$50.9 million during Q1 2025.